American Society of Clinical Oncology

SHERPA: White

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Ladanyi
    Ladanyi
  4. Miller
    Miller
  5. Yu
    Yu
  6. Arcila
    Arcila
  7. Drilon
    Drilon
  8. Solit
    Solit
  9. Berger
    Berger
  10. Rudin
    Rudin

Groups

  1. Department of Medicine (64)
  2. GSK Faculty (64)
  3. Human Oncology and Pathogenesis Program (64)
  4. Solid Tumor Oncology Division (64)
  5. Thoracic Oncology (64)
  6. Tow Center for Developmental Oncology (TCDO) (54)
  7. Epidemiology and Biostatistics (22)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  9. Biostatistics Service (19)
  10. Sloan Kettering Institute Postdocs (15)
Search Within
  1. "Human Oncology and Pathogenesis Program"
  2. "Gregory Riely"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (14)
Groups
  1. Department of Medicine (64)
  2. GSK Faculty (64)
  3. Human Oncology and Pathogenesis Program (64)
  4. Solid Tumor Oncology Division (64)
  5. Thoracic Oncology (64)
  6. Tow Center for Developmental Oncology (TCDO) (54)

More Groups

People
  1. Gregory Riely (64)
  2. Marc Ladanyi (54)
  3. Mark Kris (49)
  4. Maria Arcila (23)
  5. Helena Yu (19)
  6. Vincent Miller (19)

More People

Years
  1. 2023 (4)
  2. 2022 (4)
  3. 2021 (3)
  4. 2020 (4)
  5. 2019 (4)
  6. 2018 (5)

More Years

Publications
  1. Journal of Clinical Oncology (57)
  2. JCO Precision Oncology (7)

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer
    Meeting Abstract

    Arbour, K. C.; Ricciuti, B.; Rizvi, H.; Hellmann, M. D.; Yu, H. A.; Ladanyi, M.; Kris, M. G.; Arcila, M. E.; Rudin, C. M.; Lito, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Sato, H.; Kubota, D.; Paik, P. K.; Qiao, H.; Jungbluth, A. A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Lovly, C. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Progression-free survival estimates in non-small cell lung cancer when RECIST is unavailable: Project GENIE's integration of genomic, therapeutic and phenomic data
    Meeting Abstract

    Lavery, J. A.; Panageas, K.; LeNoue-Newton, M.; Sweeney, S.; Sheffler-Collins, S.; Rudolph, J. E.; Rizvi, H.; Schultz, N.; Lepisto, E. M.; Kehl, K. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer
    Meeting Abstract

    Arbour, K. C.; Rizvi, H.; Plodkowski, A. J.; Halpenny, D.; Hellmann, M. D.; Heller, G.; Knezevic, A.; Yu, H. A.; Ladanyi, M.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • CNS metastases in patients with MET exon 14-altered lung cancers and outcomes with crizotinib
    Journal Article

    Offin, M.; Luo, J.; Guo, R.; Lyo, J. K.; Falcon, C.; Dienstag, J.; Wilkins, O.; Chang, J.; Rudin, C. M.; Riely, G.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A. J.; Chan, J. M.; Rizvi, H.; Rekhtman, N.; Daneshbod, Y.; Kubota, D.; Chang, J. C.; Arcila, M. E.; Ladanyi, M.; Somwar, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
    Journal Article

    Offin, M.; Guo, R.; Wu, S. L.; Sabari, J.; Land, J. D.; Ni, A.; Montecalvo, J.; Halpenny, D. F.; Buie, L. W.; Pak, T.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Harnessing clinical sequencing data for survival stratification of patients with metastatic lung adenocarcinomas
    Journal Article

    Shen, R.; Martin, A.; Ni, A.; Hellmann, M.; Arbour, K. C.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Acquired BRAF fusions as a mechanism of resistance to EGFR therapy
    Meeting Abstract

    Vojnic, M.; Kurzatkowski, C.; Kubota, D.; Suzawa, K.; Liu, Z.; Mattar, M.; Khodos, I.; Poirier, J. T.; de Stanchina, E.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save